Skip to main content Accessibility help
×
Home

Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)

  • Thomas Grochtdreis (a1), Christian Brettschneider (a1), Frederike Bjerregaard (a2), Christiane Bleich (a3), Sigrid Boczor (a4), Martin Härter (a3), Lars P. Hölzel (a2) (a5), Michael Hüll (a6) (a7), Thomas Kloppe (a4), Wilhelm Niebling (a8), Martin Scherer (a4), Iris Tinsel (a8) and Hans-Helmut König (a1)...

Abstract

Background:

Late-life depression is a highly prevalent disorder that causes a large economic burden. A stepped collaborative care program was set up in order to improve care for patients with late-life depression in primary care in Germany: GermanIMPACT is the adaption of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) program that has already been established in primary care in the USA. The aim of this study was to determine the cost-effectiveness of GermanIMPACT compared with treatment as usual from a societal perspective.

Methods:

This study is part of a 12-month bi-centric cluster-randomized controlled trial aiming to assess the effectiveness of GermanIMPACT compared with treatment as usual among patients with late-life depression. A cost-effectiveness analysis using depression-free days (DFDs) was performed. Net-monetary benefit (NMB) regressions adjusted for baseline differences for different willingness-to-pay (WTP) thresholds were conducted and cost-effectiveness acceptability curves were constructed.

Results:

In total, n = 246 patients (intervention group: n = 139; control group: n = 107) with a mean age of 71 from 71 primary care practices were included in the analysis. After 12 months, adjusted mean differences in costs and DFDs between intervention group and control group were +€354 and +21.4, respectively. Only the difference in DFDs was significant (p = 0.022). According to the unadjusted incremental cost-effectiveness ratio, GermanIMPACT was dominant compared with treatment as usual. The probability of GermanIMPACT being cost-effective was 80%, 90% or 95% if societal WTP per DFD was ≥€70, ≥€110 or ≥€180, respectively.

Conclusion:

Evidence for cost-effectiveness of GermanIMPACT relative to treatment as usual is not clear. Only if societal WTP was ≥€180 for an additional DFD, GermanIMPACT could be considered cost-effective with certainty.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)
      Available formats
      ×

Copyright

Corresponding author

Corresponding author at: Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. E-mail address: t.grochtdreis@uke.de (T. Grochtdreis).

References

Hide All
[1]Luppa, MSikorski, CLuck, TEhreke, LKonnopka, AWiese, B et al. Age- and gender-specific prevalence of depression in latest-life - systematic review and meta-analysis. J Affect Disord 2012;136(3):212221.
[2]Bock, JOBrettschneider, CWeyerer, SWerle, JWagner, MMaier, W et al. Excess health care costs of late-life depression - results of the AgeMooDe study. J Affect Disord 2016; 199:139147.
[3]Olesen, JGustavsson, ASvensson, MWittchen, HUJonsson, BThe economic cost of brain disorders in Europe. Eur J Neurol 2012;19(1):155162.
[4]Luppa, MHeinrich, SAngermeyer, MCKönig, H-HRiedel-Heller, SGHealthcare costs associated with recognized and unrecognized depression in old age. Int Psychogeriatr 2008;20(6):12191229.
[5]Beekman, ATDeeg, DJBraam, AWSmit, JHVan Tilburg, WConsequences of major and minor depression in later life: a study of disability, well-being and service utilization. Psychol Med 1997;27(6):13971409.
[6]Schulz, RDrayer, RARollman, BLDepression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry 2002;52(3):205225.
[7]Unützer, JPatrick, DLDiehr, PSimon, GGrembowski, DKaton, WQuality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr 2000;12(1):1533.
[8]Waern, MRuneson, BSAllebeck, PBeskow, JRubenowitz, ESkoog, I et al. Mental disorder in elderly suicides: a case-control study. Am J Psychiatry 2002;159(3):450455.
[9]Blazer, DGDepression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003;58(3):249265.
[10]Glaesmer, HGunzelmann, TMartin, ABrahler, ERief, WDie Bedeutung psychischer Beschwerden für die medizinische Inanspruchnahme und das Krankheitsverhalten Älterer. Psychiat Prax 2008;35(4):187193.
[11]NICE, Depression in adults. The treatment and management of depression in adults 2009, National Institute for Health and Clinical Excellence London (UK).
[12]DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolareunipolare Depression - langfassung 2015, Leitliniengruppe Unipolare Depression Berlin, Düsseldorf.
[13]Katon, WJSchoenbaum, MFan, M-YCallahan, CMWilliams, J Jr.Hunkeler, E et al. The IMPACT investigators. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry 2005;62(12):13131320.
[14]Unützer, JKaton, WCallahan, CMWilliams, J Jr.Hunkeler, EHarpole, L et al. The IMPACT investigators. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002;288(22):28362845.
[15]Hölzel, LPBjerregaard, FTinsel, IKloppe, TBoczor, SBleich, C et al. Coordinated treatment of depression in elderly people in primary care. A cluster-randomized, controlled study (GermanIMPACT). Dtsch Arztebl Int 2018;115(44):741747.
[16]Wernher, IBjerregaard, FTinsel, IBleich, CBoczor, SKloppe, T et al. Collaborative treatment of late-life depression in primary care (GermanIMPACT): study protocol of a cluster-randomized controlled trial. Trials 2014; 15:351.
[17]Bosmans, JEDozeman, Evan Marwijk, HWJvan Schaik, DJFStek, MLBeekman, ATF et al. Cost-effectiveness of a stepped care programme to prevent depression and anxiety in residents in homes for the older people: a randomised controlled trial. Int J Geriatr Psychiatry 2014;29(2):182190.
[18]van der Weele, GMde Waal, MWMvan den Hout, WBde Craen, AJMSpinhoven, PStijnen, T et al. Effects of a stepped-care intervention programme among older subjects who screened positive for depressive symptoms in general practice: the PROMODE randomised controlled trial. Age Ageing 2012;41(4):482488.
[19]van’t Veer-Tazelaar, PSmit, Fvan Hout, Hvan Oppen, Pvan der Horst, HBeekman, A et al. Cost-effectiveness of a stepped care intervention to prevent depression and anxiety in late life: randomised trial. BJP 2010;196(4):319325.
[20]Grochtdreis, TBrettschneider, CWegener, AWatzke, BRiedel-Heller, SHärter, M et al. Cost-effectiveness of collaborative care for the treatment of depressive disorders in primary care: a systematic review. PLoS One 2015;10(5): e0123078.
[21]Löwe, BSpitzer, RLZipfel, SHerzog, WGesundheitsfragebogen für patienten (PHQ-D) 2nd ed. 2002, Manual und Testunterlagen Karlsruhe: Pfizer.
[22]Alexopoulos, GSRaue, PJKiosses, DNMackin, RSKanellopoulos, DMcCulloch, C et al. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. Arch Gen Psychiatry 2011;68(1):3341.
[23]D’Zurilla, TJGoldfried, MRProblem solving and behavior modification. J Abnorm Psychol 1971;78(1):107126.
[24]Kroenke, KSpitzer, RLWilliams, JBThe PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606613.
[25]Spitzer, RLKroenke, KWilliams, JBValidation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 1999;282(18):17371744.
[26]Gräfe, KZipfel, SHerzog, WLöwe, BScreening psychischer störungen mit dem “Gesundheitsfragebogen für patienten (PHQ-D)“. Diagnostica 2004;50(4):171181.
[27]The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199208.
[28]König, H-HHeider, DLehnert, TRiedel-Heller, SGAngermeyer, MCMatschinger, H et al. The ESEMeD/MHEDEA investigators. Health status of the advanced elderly in six European countries: results from a representative survey using EQ-5D and SF-12. Health Qual Life Outcomes 2010; 8:143.
[29]van Leeuwen, KMBosmans, JEJansen, APHoogendijk, EOvan Tulder, MWvan der Horst, HE et al. Comparing measurement properties of the EQ-5D-3L, ICECAP-O, and ASCOT in frail older adults. Value Health 2015;18(1):3543.
[30]Dolan, PModeling valuations for EuroQol health states. Med Care 1997;35(11):10951108.
[31]Seidl, HBowles, DBock, JOBrettschneider, CGreiner, WKönig, H-H et al. FIMA-fragebogen zur erhebung von gesundheitsleistungen im alter: entwicklung und pilotstudie. Gesundheitswesen 2015;77(1):4652.
[32]Kroenke, KSpitzer, RLWilliams, JBWLöwe, BThe patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry 2010;32(4):345359.
[33]Rigler, SKStudenski, SWallace, DReker, DMDuncan, PWCo-morbidity adjustment for functional outcomes in community-dwelling older adults. Clin Rehabil 2002;16(4):420428.
[34]Vannoy, SDArean, PUnützer, JAdvantages of using estimated depression-free days for evaluating treatment efficacy. Psychiatr Serv 2010;61(2):160163.
[35]Mallick, RChen, JEntsuah, ARSchatzberg, AFDepression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry 2003;64(3):321330.
[36]Lave, JRFrank, RGSchulberg, HCKamlet, MSCost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998;55(7):645651.
[37]Bock, JOBrettschneider, CSeidl, HBowles, DHolle, RGreiner, W et al. Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische evaluation. Gesundheitswesen 2015;77(1):5361.
[38]Statistisches Bundesamt, Preise. Verbraucherpreisinidzes für Deutschland. Lange reihen ab 1948 April 2015 2015, Statistisches Bundesamt Wiesbaden.
[39]The World Bank World development indicators: size of the economy 2013, The World Bank Washington, DC.
[40]Die Rote Liste Service GmbH, ROTE LISTE 2014: Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte) 2014, Die Rote Liste Service GmbH Frankfurt am Main.
[41]Statistisches Bundesamt, Verdienste und Arbeitskosten. Verdienststrukturen 2010 2013, Statistisches Bundesamt Wiesbaden.
[42]Statistisches Bundesamt, Verdienste und Arbeitskosten. Arbeitskosten im Produzierenden Gewerbe und im Dienstleistungsbereich - Ergebnisse für Deutschland- 2012 2015, Statistisches Bundesamt Wiesbaden.
[43]StataCorp, Stata multiple impuatation reference manual. Release 13 2013, StataCorp LP College Station, TX.
[44]Drummond, MFSculpher, MJTorrance, GWO’Brien, BJStoddart, GLMethods for the economic evaluation of health care programmes 3rd ed. 2005, Oxford University Press Oxford, New York.
[45]Zellner, AAn efficient method of estimating seemingly unrelated regressions and tests for aggregation bias. J Am Stat Assoc 1962;57(298): 348-&.
[46]Tambour, MZethraeus, NJohannesson, MA note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998;14(3):467471.
[47]Lothgren, MZethraeus, NDefinition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000;9(7):623630.
[48]Brazier, JConnell, JPapaioannou, DMukuria, CMulhern, BPeasgood, T et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess 2014;18(34):1188.
[49]Grochtdreis, TBrettschneider, CHajek, ASchierz, KHoyer, JKönig, H-HMapping the beck depression inventory to the EQ-5D-3L in patients with depressive disorders. J Ment Health Policy Econ 2016;19(2):7989.
[50]Hoch, JSBriggs, AHWillan, ARSomething old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11(5):415430.
[51]Unützer, JKaton, WJRusso, JSimon, GVon Korff, MLin, E et al. Willingness to pay for depression treatment in primary care. Psychiatr Serv 2003;54(3):340345.
[52]Rubin, DBMultiple imputation for nonresponse in surveys 1987, John Wiley & Sons New York.
[53]Little, RJRubin, DBCausal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21:121145.
[54]Huijbregts, KMde Jong, FJvan Marwijk, HWBeekman, ATAder, HJHakkaart-van Roijen, L et al. A target-driven collaborative care model for Major depressive disorder is effective in primary care in the Netherlands. A randomized clinical trial from the depression initiative. J Affect Disord 2013;146(3):328337.
[55]Richards, DAHill, JJGask, LLovell, KChew-Graham, CBower, P et al. Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial. BMJ 2013; 347:f4913.

Keywords

Related content

Powered by UNSILO

Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)

  • Thomas Grochtdreis (a1), Christian Brettschneider (a1), Frederike Bjerregaard (a2), Christiane Bleich (a3), Sigrid Boczor (a4), Martin Härter (a3), Lars P. Hölzel (a2) (a5), Michael Hüll (a6) (a7), Thomas Kloppe (a4), Wilhelm Niebling (a8), Martin Scherer (a4), Iris Tinsel (a8) and Hans-Helmut König (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Cost-effectiveness analysis of collaborative treatment of late-life depression in primary care (GermanIMPACT)

  • Thomas Grochtdreis (a1), Christian Brettschneider (a1), Frederike Bjerregaard (a2), Christiane Bleich (a3), Sigrid Boczor (a4), Martin Härter (a3), Lars P. Hölzel (a2) (a5), Michael Hüll (a6) (a7), Thomas Kloppe (a4), Wilhelm Niebling (a8), Martin Scherer (a4), Iris Tinsel (a8) and Hans-Helmut König (a1)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *